Tabula Rasa HealthCare Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Oct 04, 2016 20:20 pm UTC| Business

MOORESTOWN, N.J., Oct. 04, 2016 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication...

REGENXBIO to Present at the Jefferies Gene Editing and Gene Therapy Summit

Oct 04, 2016 20:16 pm UTC| Business

ROCKVILLE, Md., Oct. 04, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based...

Navient announces $509 million FFELP ABS legal final maturity date extension, bringing total bonds extended to $7.3 billion

Oct 04, 2016 20:15 pm UTC| Business

WILMINGTON, Del., Oct. 04, 2016 -- Navient (Nasdaq:NAVI), the nation’s leading loan management, servicing and asset recovery company, today announced an amendment extending the final maturity date of $509 million in...

Griffin-American Healthcare REIT IV Acquires Medical Office Buildings in Michigan and Alabama

Oct 04, 2016 20:15 pm UTC| Business

IRVINE, Calif., Oct. 04, 2016 -- American Healthcare Investors and Griffin Capital Corporation, the co-sponsors of Griffin-American Healthcare REIT IV, Inc., announced today that the REIT has acquired Rochester Hills...

Triangle Capital Corporation Announces Conference Call and On-Demand Podcast to Discuss Third Quarter 2016 Results

Oct 04, 2016 20:15 pm UTC| Business

RALEIGH, N.C., Oct. 04, 2016 -- Triangle Capital Corporation (NYSE:TCAP) (“Triangle” or the “Company”), a leading provider of capital to lower middle market companies, today announced it has scheduled a conference call...

BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9

Oct 04, 2016 20:15 pm UTC| Business

WALTHAM, Mass., Oct. 04, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that...

Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting

Oct 04, 2016 20:15 pm UTC| Business

—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae approximately 49 percent;...